Smith & Nephew plc
Financials
Valuation Metrics
Smith & Nephew plc's Market Cap is $12.87B. At end of 2025 it was $14.22B. Ranked #779 of 3,116 in US market (top 25%), #533 of 1,644 on NYSE (top 32%), #52 of 203 in Health Care Equipment & Services (top 26%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $12.87B | US#779/3,116 Sec#52/203 |
| Revenue | $6.16B | US#778/3,116 Sec#44/203 |
| Net Income | $625M | US#733/3,116 Sec#42/203 |
| Total Assets | $10.46B | US#964/3,116 Sec#47/203 |
| Net Assets | $5.29B | US#665/3,116 Sec#39/203 |
| Employees | 18,362 | US#588/3,116 Sec#41/203 |
| Value | ||
| P/E | 20.59x | US#1,142/3,116 Sec#24/203 |
| P/B | 2.43x | US#1,511/3,116 Sec#65/203 |
| PEG | 0.40x | US#510/3,116 Sec#18/203 |
| P/S | 2.09x | US#1,306/3,116 Sec#86/203 |
| EV/EBITDA | 11.71x | US#1,068/3,116 Sec#29/203 |
| FCF Yield | 6.62% | US#1,063/3,116 Sec#42/203 |
| Profitability | ||
| ROE | 11.82% | US#1,168/3,116 Sec#57/203 |
| ROA | 5.98% | US#916/3,116 Sec#59/203 |
| Op. Margin | 12.88% | US#1,349/3,116 Sec#53/203 |
| Revenue Growth | 6.09% | US#1,660/3,116 Sec#120/203 |
| Earnings Growth | 51.70% | US#488/3,116 Sec#24/203 |
| Financial Health | ||
| Debt Ratio | 97.71% | US#1,071/3,116 Sec#102/203 |
| Total Debt | $3.33B | US#888/3,116 Sec#42/203 |
| FCF | $852M | US#656/3,116 Sec#40/203 |
| Cash | $557M | US#1,000/3,116 Sec#52/203 |
| Current Ratio | 2.57x | US#926/3,116 Sec#94/203 |
| Net Debt/EBITDA | 2.07x | US#1,352/3,116 Sec#84/203 |
| Dividend | ||
| Div. Yield | 2.56% | US#748/3,116 Sec#8/203 |
| Div. Growth | 0.92% | US#1,148/3,116 Sec#39/203 |
| Performance | ||
| 1Y Return | -17.84% | US#2,278/3,116 Sec#154/203 |
| 1M Return | 14.50% | US#517/3,116 Sec#48/203 |
| From 52W High | -18.44% | US#1,419/3,116 Sec#119/203 |
| 1Y MDD | -28.63% | US#1,207/3,116 Sec#54/203 |
| Trading | ||
| Volume | 1,676,214 shares | US#1,160/3,116 Sec#68/203 |
| Trading Value | $50M | US#1,392/3,116 Sec#103/203 |
| Per Share | ||
| EPS | $1.47 | US#1,515/3,116 Sec#79/203 |
| BPS | $12.43 | US#1,672/3,116 Sec#94/203 |
Company Info
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.